Researchers are working towards learning the changes in non-small cell lung cancer (NSCLC) to specifically target those changes. Epidermal growth factor receptor (EGFR) provides new insights towards lung cancer therapies. EGFR targeting drugs work to slow down the growth of tumor by helping the cells to grow and divide. The EGFR testing helps to predict the benefit of treating patients with NSCLC with EGFR tyrosine kinase inhibitor. EGFR plays a vital role in advancing NSCLC research initiatives, treatment and patient outcome. As some NSCLC cells have too much EGFR, the drugs called as EGFR inhibitors help to block the signal that tells them to grow.
EGFR is a transmembrane receptor tyrosine kinase protein and belongs to the erbB family of closely related tyrosine kinases. Research has shown that EGFR group of growth factors as key molecules that promote lung cancer generation and propagation. Thus, the EGFR receptor tyrosine kinases help to trigger signaling events for both NSCLC and SCLC. EGFR functions by way of inactivation of intracellular TK signaling and use of neutralizing antibodies against EGFR. The common inactivators for lung cancer include Erlotinib and Gefitinib. They are effective in suppressing proliferation of malignant lung cells and reducing lung cancer metastasis. These drugs can be used as the first treatment for advanced NSCLC having certain mutations in the EGFR gene.
The common side effects of EGFR inhibitors cover skin problems such as acne-like rashes on face and chest; diarrhea, mouth sores, and more. You should consult your doctor immediately if you face any serious side effect.
What do you think about the available treatment for lung cancer? Share your thoughts with us in the comments section below.
The information offered in this post is for educational purposes only and is not a substitute for medical advice. It is advised to talk to your health care professional before start or stop of any medicine or drug.